We are a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Enhancing Survival Through Innovative Immune Modulation
We are a late-stage clinical company developing microbiome therapies to modulate the immune system and improve cancer survival.
See News
Corporate profile
Press Releases
April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034
MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…
Media Coverage
April 15, 2025: Le Journal des biotechs : Hervé Affagard (Maat Pharma), Frédéric Gomez (Pharmium Securities) – Boursorama (French Only)
April 1, 2025: MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies – BioTuesdays
February 20, 2025: Hervé Affagard talks Phase 3 results, the regulatory landscape and industry collaborations – Microbiome Times
Posters
MaaT034, a new co-cultured microbiome ecosystem therapy candidate, safely colonizes the gastro-intestinal tract of germ-free mice to restore a healthy gut physiology and stimulates immunity
Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from Early Access Program in Europe
MaaT033 to ensure optimal intestinal microbiota to improve survival of patients receiving allo-HSCT: PHOEBUS trial
